Moreover, our study demonstrates that either genetic deletion of VISTA in the host or its blockade with different antibodies leads to enhanced HNC control by RT and prolonged survival in tumor-bearing mice, suggesting that targeting VISTA could overcome RT resistance mediated by myeloid cell immunosuppression. The gene discussed is VSIR; the disease is neoplasm.